| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Observational Study |
| Article Title |
Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Gang Wang, Fang-Ying Ning, Jia-Heng Wang, Hai-Meng Yan, Hong-Wei Kong, Yu-Ting Zhang and Qiang Shen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Excellent Young Medical Talents from the Quzhou People’s Hospital |
|
|
| Corresponding Author |
Fang-Ying Ning, MD, Doctor, Doctor, Department of Hematology, People’s Hospital of Hangzhou Medical College, Zhejiang Provincial People’s Hospital, NO .158 Shangtang Road, Xiacheng District, Hangzhou 310000, Zhejiang Province, China. ningfangying2011@163.com |
| Key Words |
Multiple myeloma; Interleukin-32; Minimal residual lesions; Progression-free survival; Overall survival; Prognosis |
| Core Tip |
Multiple myeloma (MM) is a heterogeneous disease with large differences in survival time from several months to 20 years, and its clinical manifestations are complex. There are many factors affecting the prognosis. International Staging System and Durie-Salmon staging has been established to assess the prognosis of the disease, but the accuracy of β2-microglobulin and albumin was controversial. In recent years, new prognostic indicators of MM are being continuously explored. Studies have shown that associated with renal function, degree of bone destruction, and hypercalcemia, which can reveal the prognosis of MM and predict the overall survival (OS). Moreover, minimal residual disease can also predict OS and progression-free survival in patients with MM. We collected the data from MM patients in our hospital, analyzed their clinical efficacy, follow-up results and laboratory examination indicators, and suggested that interleukin-32 can be used as an auxiliary indicator for post-treatment efficacy and prognosis assessment. |
| Publish Date |
2019-12-25 11:24 |
| Citation |
Wang G, Ning FY, Wang JH, Yan HM, Kong HW, Zhang YT, Shen Q. Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance. World J Clin Cases 2019; 7(24): 4234-4244 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i24/4234.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i24.4234 |
